The table below provides a list of the drugs associated with non-serious adverse events identified in the scientific literature over the last week.
| Non-serious case reports | Adverse event(s) | No. of cases |
|---|---|---|
| Drug name(s) | ||
| Ambroxol, Betamethasone, Ibuprofen, Magnesium hydroxide, Methylprednisolone acetate, Paracetamol, PEG 3000, PEG 3350, PEG 400, PEG 4000, PEG 6000, Phenoxymethylpenicillin, Poloxamer 407, Polyethylene glycol, Polysorbate 80, Sodium fluoride, Tolfenamic acid, Venlafaxine | Hypersensitivity, Urticaria | 8 |
| Apremilast | Weight loss | 1 |
| Arginine, Epoprostenol, Sodium chloride | Cough, Respiratory tract disorders | 1 |
| Avibactam/ceftazidime | Nausea and vomiting | 1 |
| AZD 1222 | Alopecia | 1 |
| BBIBP CorV | Eosinophilia, Panniculitis | 1 |
| Bexarotene | Anaemia, Diarrhoea, Hypercholesterolaemia, Nausea, Oedema | 1 |
| Botulinum Toxin A | Neuromuscular disorders | 1 |
| Botulinum Toxin A, Erenumab | Alopecia, Constipation, Dizziness, Fatigue, Insomnia, Skin disorders | 6 |
| Brentuximab vedotin | Guttate psoriasis | 1 |
| Camrelizumab | Immunological disorders | 1 |
| Canakinumab | Lymphopenia | 1 |
| Carbamazepine, Lacosamide | Asthenia, Dizziness, Drowsiness | 1 |
| Cenobamate, Clobazam, Lacosamide, Lamotrigine, Valproic acid | Ataxia, Dizziness, Drowsiness, Mental disorders | 5 |
| Chlorpromazine | Dizziness | 1 |
| Clarithromycin | Exanthema | 1 |
| Cobimetinib, Vemurafenib | Exanthema | 5 |
| Cotrimoxazole | Fixed drug eruptions | 1 |
| COVID 19 Vaccine Pfizer BioNTech | Pustular psoriasis | 2 |
| COVID 19 Vaccine Pfizer BioNTech | Thyroiditis | 1 |
| Cytarabine/daunorubicin | Exanthema | 2 |
| Dimethyl fumarate | Herpes zoster | 2 |
| Dinalbuphine sebacate | Injection site pain, Injection site reactions | 1 |
| Docetaxel | Radiodermatitis | 1 |
| Donepezil, Resveratrol | Asthenia, Diarrhoea, Dizziness, Nausea | 4 |
| Duloxetine, Quetiapine, Risperidone | Dizziness, Drowsiness, Hypotension, Neurological disorders | 1 |
| Elasomeran | Inflammation, Skin disorders, Tumours | 1 |
| Erenumab | Erythema, Haematoma, Injection site reactions | 2 |
| Gadoterate meglumine, Gadoxetate disodium | Respiration disorders | 2 |
| Heparin | Thrombocytopenia | 3 |
| Hyaluronic acid | Erythema, Oedema | 1 |
| Hydrocortisone, Prednisolone acetate | Eye Disorders | 1 |
| Infliximab, Ustekinumab | Hypersensitivity | 1 |
| Ixekizumab | Injection site reactions | 1 |
| Ketamine | Dizziness, Dysphoria, Nausea | 4 |
| Lenalidomide | Hypersensitivity | 1 |
| Levetiracetam | Agitation, Vomiting | 2 |
| Levetiracetam | Somnolence | 1 |
| Levodopa | Dyskinesias | 1 |
| Lutetium 177 PSMA imaging and therapy | Lethargy, Xerostomia | 1 |
| Methylprednisolone acetate | Allergic contact dermatitis | 1 |
| Morphine, Paracetamol | Drowsiness, Somnolence | 1 |
| Olanzapine | Weight gain | 1 |
| Olanzapine, Oxcarbazepine, Semaglutide, Sertraline, Topiramate | Appetite disorders, Nausea, Somnolence | 2 |
| Pembrolizumab | Anaemia | 1 |
| Pembrolizumab | Pneumonitis | 1 |
| Rituximab | Serum sickness | 1 |
| Sonidegib | Alopecia, Diarrhoea | 2 |
| Tozinameran | Henoch Schoenlein purpura | 1 |
| Tozinameran | Lymphadenopathy | 1 |
| Tozinameran | Pityriasis rosea | 2 |
| Vildagliptin | Contact dermatitis | 2 |
Reference
- Non-serious case reports. Reactions Weekly 4 May 2022